Date: 2013-11-05
Type of information: R&D agreement
Compound:
Company: Evotec (Germany) The Leukemia & Lymphoma Society (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On November 5, 2013, Evotec has announced that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society (“LLS”). Evotec will support one of LLS’s Screen-to-Lead Programs (“SLP”). In this collaboration, Evotec partners with LLS to support selected programmes and principal investigators with resources for high-throughput screening and optimisation of small molecules into drug-like compounds. Evotec delivers an industrialised, cutting-edge, comprehensive and unbiased drug discovery infrastructure to support innovation efficiency as part of a fully integrated solution.
Financial terms: No financial details were disclosed.
Latest news:
